Survival Outcomes in Patients With Locally Advanced NSCLC Converted to Resectable Disease by Neoadjuvant Therapy

ECE DUYGU GULSEN; RASHAD ISMAYILOV; AYDAN FARZALIYEVA; MEHMET NEZIR RAMAZANOGLU; ARZU OGUZ; DALOKAY KILIC; ZAFER AKCALI; OZDEN ALTUNDAG

doi:10.21873/invivo.14216

Article Information

vol. 40 no. 1 522-531

DOI

https://doi.org/10.21873/invivo.14216

PMID

41482392

Published By

International Institute of Anticancer Research

Print ISSN

0258-851X

Online ISSN

1791-7549

History

Received July 19, 2025
Revision received August 11, 2025
Accepted August 18, 2025
Published online January 2, 2026.

Copyright © 2026 The Author(s). Published by the International Institute of Anticancer Research. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

Author Information

ECE DUYGU GULSEN¹,
RASHAD ISMAYILOV² ⇑,
AYDAN FARZALIYEVA²,
MEHMET NEZIR RAMAZANOGLU²,
ARZU OGUZ²,
DALOKAY KILIC³,
ZAFER AKCALI² and
OZDEN ALTUNDAG²

¹Department of Internal Medicine, Baskent University Faculty of Medicine, Ankara, Türkiye;
²Department of Medical Oncology, Baskent University Faculty of Medicine, Ankara, Türkiye;
³Department of Thoracic Surgery, Baskent University Faculty of Medicine, Ankara, Türkiye

Rashad Ismayilov (ORCiD: 0000-0002-7093-2722), MD, Department of Medical Oncology, Baskent University Ankara Hospital, Yukarı Bahçelievler, Mareşal Fevzi Çakmak Cd. 10. Sk. No. 45, 06490 Bahçelievler Ankara, Türkiye. Tel: +90 5070331995, e-mail: rismayilov{at}baskent.edu.tr

View Full Text